Aliskiren

Aliskiren is a direct renin inhibitor used to manage hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.

Chemical structure of Aliskiren
Mechanism
Curator reviewed · 3 references
Primary indication
Aliskiren is used for the treatment of hypertension in children above 6 years and adults.Curator reviewed · 3 structured indications
Formula / weight
C30H53N3O6 · 551.7583 g/mol (avg)
First approval
Canada, 2015 · United States, 2007 · European Union, 2016
Code names
CGP 60536 · CGP60536B · SPP 100
Brand names
  • Rasilez
  • Tekturna
  • Tekturna Hct

Resolves to

Structure
InChIKeyUXOWGYHJODZGMF-QORCZRPOSA-NSMILESCOCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1
Targets
Transporters

What you can answer from here — as of September 14, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
1,221Drug interactionsStructured to mechanism, not free text
Sign in
100Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
4ContraindicationsEach with its own population and attribute set
Sign in
306Marketed productsAcross 5 countries and 12 labellers
Sign in
5ATC codesIncluding every combination product, plus 19 drug categories
Sign in
29+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Aliskiren, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account